



CORRIGENDUM

# User assessment of Norditropin NordiFlex<sup>®</sup>, a new prefilled growth hormone pen: a Phase IV multicenter prospective study [Corrigendum]

Tauber M, Jaquet D, Jesuran-Perelroizen M, Petrus M, Bertrand AM, Coutant R. *Patient Preference and Adherence*. 2013;7:455–462.

On pages 455; 456; 458 and 459 NordiFlex manufacturer's details were incorrectly listed as "Novo Nordisk, Princeton, NY, USA". The correct manufacturer's details are "Novo Nordisk A/S, Bagsværd, Denmark".

Patient Preference and Adherence downloaded from <https://www.dovepress.com/>  
For personal use only.

## Patient Preference and Adherence

### Publish your work in this journal

Patient Preference and Adherence is an international, peer-reviewed, open access journal focusing on the growing importance of patient preference and adherence throughout the therapeutic continuum. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to

optimize clinical outcomes for existing disease states are major areas of interest. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/patient-preference-and-adherence-journal>